← Back to Search

Sweetener

Steviol Glycosides for Obesity

N/A
Waitlist Available
Research Sponsored by Midwest Center for Metabolic and Cardiovascular Research
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 weeks
Awards & highlights

Study Summary

This trial is testing the effects of steviol glycoside, a sugar substitute, on blood sugar, hormones, and gut function in people with normal weight, overweight, and type 2 diabetes.

Who is the study for?
This trial is for men and women aged 18-50 with different body weights: normal (BMI 18.5-24.9), overweight (BMI 25.0-29.9), or type 2 diabetes patients with BMI up to 34.9 and HbA1c <8%. Participants should have a low intake of sweetened drinks, not be on certain medications, and willing to avoid alcohol, vigorous exercise, tobacco use before visits.Check my eligibility
What is being tested?
The study tests the effects of steviol glycosides alone or combined with glucose on blood sugar levels and hormone release compared to water and glucose in individuals who are normal weight, overweight, or have type 2 diabetes.See study design
What are the potential side effects?
While specific side effects aren't listed for this trial, participants may experience changes in appetite hormones which could affect hunger levels or gastrointestinal discomfort due to the ingestion of various test substances.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Gastric inhibitory polypeptide
Glucagon
Glucagon-like peptide 1
+3 more

Side effects data

From 2014 Phase 4 trial • 106 Patients • NCT02054325
51%
Hyperpigmentation
100%
80%
60%
40%
20%
0%
Study treatment Arm
Polidocanol With Glucose
Glucose

Trial Design

3Treatment groups
Experimental Treatment
Group I: Type 2 Diabetes Mellitis GroupExperimental Treatment4 Interventions
The T2DM group includes men and women with BMI 25.0 - 34.9 kg/m2, HbA1c <8%, and will receive all interventions.
Group II: Overweight GroupExperimental Treatment4 Interventions
The overweight group includes men and women with BMI 25.0 - 29.9 kg/m2, and will receive all interventions.
Group III: Normal Weight GroupExperimental Treatment5 Interventions
The normal weight group incudes men and women with BMI 18.5 - 24.9 kg/m2, and will receive all interventions.

Find a Location

Who is running the clinical trial?

Midwest Center for Metabolic and Cardiovascular ResearchLead Sponsor
20 Previous Clinical Trials
779 Total Patients Enrolled
CargillIndustry Sponsor
27 Previous Clinical Trials
3,162 Total Patients Enrolled
Kevin Maki, PhDStudy DirectorMB Clinical Research & Consulting, LLC
12 Previous Clinical Trials
993 Total Patients Enrolled
~22 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top